Adcock Unhappy With Single Exit Price But Scoops ZAR1.8bn From ARV Tender
Growing its portfolio of established brands and expanding its product range through the acquisition of non-regulated brands are at the top of Adcock Ingram’s wish-list in 2019, as the company grapples with what it feels is a “low” increase in South Africa’s single exit price and tough trading conditions in certain channels. Nevertheless, it saw a “sound” financial performance in the six months to 31 December 2018.
You may also be interested in...
South African body the Health Funders Association (HFA), which represents local stakeholders involved in funding private healthcare, has announced strong opposition to “any interim increase in medicine costs this year”. This comes in the wake of lobbying of government by industry for a further increase in the 2018 single exit price (SEP).
South Africa’s Adcock Ingram says it is “engaging constructively” with the Pricing Committee of the country’s National Department of Health to see if any “short-term relief” will be available on the country’s single exit price (SEP), amidst “concern” over the recent fall in the value of the rand and rising costs at the company.
Five generics manufacturers have signed sublicensing agreements with the Medicines Patent Pool (MPP) enabling the firms to develop and sell dolutegravir in “more than 100 developing countries”. Among the companies are South Africa’s Adcock Ingram and South Korea’s Celltrion, the first firms from these regions to enter sub-licensing deals with the Pool. The others are China’s Langhua Pharma, plus Arene Lifesciences and Mangalam Drugs & Organics in India.